IDO & TDO Inhibitors - Novel Immune Response Checkpoint Modulators

IDO & TDO Inhibitors - Novel Immune Response Checkpoint Modulators provides a competitor analysis as of March 2015 in the development pipeline of novel inhibitors of indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3- dioxygenase (TDO) for treatment of cancer as monotherapy and in combination with other immune checkpoint inhibitors.